Morbidity and mortality are classically used to measure disease burden. However, the allocation of limited health-care resources demands an agreed rational allocation principle and, consequently, the setting of priorities is of considerable importance. We collected data from the national death certificate database, and the national health insurance claim database and life tables. Using this data, we calculated disability adjusted life year (DALY) and health life year (HeaLY) values for smoking-related cancer. The burden of cancer due to smoking was estimated by multiplying the population attributable risk due to smoking by the DALY and HeaLY results for cancers. The burden of cancer due to smoking for Korean men was 1930.1 person-years by DALY and 1681.3 person-years by HeaLY per 100 000 people. Similarly, the burden of cancer due to smoking for Korean women was 352.6 person-years for DALY and 313.6 person-years for HeaLY per 100 000 people. Priority rankings for cancer burden due to smoking was somewhat different by DALY and HeaLY. The largest health gap for men was stomach cancer by DALY and lung cancer by HeaLY, whereas for women it was lung cancer by both methods. This study provides a rational basis for national cancer policy planning by presenting the priority burden of cancers caused by smoking.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11159800 | PMC |
http://dx.doi.org/10.1111/j.1349-7006.2006.00205.x | DOI Listing |
Hum Mol Genet
January 2025
Laboratory Medicine and Pathology, University of Minnesota, 420 Delaware Street SE, Minneapolis, MN, 55455, USA.
Background: Individuals with cystic fibrosis (CF; a recessive disorder) have an increased risk of colorectal cancer (CRC). Evidence suggests individuals with a single CFTR variant may also have increased CRC risk.
Methods: Using population-based studies (GECCO, CORECT, CCFR, and ARIC; 53 785 CRC cases and 58 010 controls), we tested for an association between the most common CFTR variant (Phe508del) and CRC risk.
J Hematol Oncol
January 2025
Bavarian Cancer Research Center (BZKF), R/R ALL Study Group, Bavaria, Germany.
Anti-CD19 chimeric antigen receptor T cells (CAR) are a well-established treatment option for children and young adults suffering from relapsed/refractory B-lineage acute lymphoblastic leukemia. Bridging therapy is used to control disease prior to start of lymphodepletion before CAR infusion and thereby improve efficacy of CAR therapy. However, the effect of different bridging strategies on outcome, side effects and response to CAR therapy is still poorly understood.
View Article and Find Full Text PDFBreast Cancer Res
January 2025
Department of Cancer Biology, Loyola University Chicago Stritch School of Medicine, Maywood, IL, 50153, USA.
Resistance to endocrine therapies remains a major clinical hurdle in breast cancer. Mutations to estrogen receptor alpha (ERα) arise after continued therapeutic pressure. Next generation selective estrogen receptor modulators and degraders/downregulators (SERMs and SERDs) show clinical efficacy, but responses are often non-durable.
View Article and Find Full Text PDFJ Gen Intern Med
January 2025
Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA.
Background: COVID-19 increased the burden of childcare on parents, leaving women vulnerable to increased disparities in the division of domestic labor. Women healthcare workers may be at heightened risk of worsening gender parity in the workplace as a result.
Objective: To examine the impact of the COVID-19 pandemic on gender parity in the division of household responsibilities among women healthcare workers.
Sci Rep
January 2025
Department of Neurosurgery, University Hospital Tübingen, Tübingen, Germany.
To compare 1D (linear) tumor volume calculations and classification systems with 3D-segmented volumetric analysis (SVA), focusing specifically on their effectiveness in the evaluation and management of NF2-associated vestibular schwannomas (VS). VS were clinically followed every 6 months with cranial, thin-sliced (< 3 mm) MRI. We retrospectively reviewed and used T1-weighted post-contrast enhanced (gadolinium) images for both SVA and linear measurements.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!